INVO Fertility (NASDAQ:IVF – Get Free Report) and Nemaura Medical (NASDAQ:NMRD – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.
Risk & Volatility
INVO Fertility has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for INVO Fertility and Nemaura Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INVO Fertility | 1 | 0 | 0 | 0 | 1.00 |
| Nemaura Medical | 0 | 0 | 0 | 0 | 0.00 |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INVO Fertility | $6.53 million | 0.54 | -$9.10 million | ($93.14) | -0.01 |
| Nemaura Medical | $3,017.00 | 1.34 | -$14.14 million | ($0.39) | 0.00 |
INVO Fertility has higher revenue and earnings than Nemaura Medical. INVO Fertility is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are held by institutional investors. 0.6% of INVO Fertility shares are held by company insiders. Comparatively, 40.4% of Nemaura Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares INVO Fertility and Nemaura Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| INVO Fertility | -422.11% | N/A | -90.34% |
| Nemaura Medical | N/A | N/A | N/A |
Summary
Nemaura Medical beats INVO Fertility on 6 of the 11 factors compared between the two stocks.
About INVO Fertility
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
About Nemaura Medical
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Receive News & Ratings for INVO Fertility Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Fertility and related companies with MarketBeat.com's FREE daily email newsletter.
